Compare Citius Pharmaceuticals Inc (CTXR) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Royal Caribbean Cruises Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Royal Caribbean Cruises Ltd trades at $284 (market cap $75.92B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 5185.8× Citius Pharmaceuticals Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.77% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | RCL | |
|---|---|---|
Market Cap | $14.64M | $75.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $365.84 |
52-Week Low | $0.53 | $246.71 |
Enterprise Value | $10.86M | $97.20B |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Royal Caribbean (RCL) trades at $288.61, up 1.14% today, with a bullish technical setup near key resistance at $292. The company demonstrates strong fundamental momentum, with 2025 revenue reaching $17.93 billion and net income surging to $4.27 billion, yielding a robust 24.36% net margin. Analyst consensus is positive, with a $328 price target implying 14% upside, supported by 25 buy ratings. Recent news highlights Caribbean demand strength offsetting European softness, with Q2 2026 earnings due July 28.
RCL's outlook is favorable, driven by earnings beats, expanding margins, and strategic destination investments. Key risks include Europe demand volatility, high debt levels, and competitive pressures. Institutional sentiment leans bullish, but macroeconomic sensitivity and execution on yield growth remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
